{"id":942845,"date":"2026-03-09T07:04:43","date_gmt":"2026-03-09T11:04:43","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-reports-full-year-2025-financial-results-and-provides-business-update\/"},"modified":"2026-03-09T07:04:43","modified_gmt":"2026-03-09T11:04:43","slug":"cartesian-therapeutics-reports-full-year-2025-financial-results-and-provides-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-reports-full-year-2025-financial-results-and-provides-business-update\/","title":{"rendered":"Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update"},"content":{"rendered":"
\n

\n Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis<\/em>\n <\/p>\n

\n Phase 2 TRITON trial of Descartes-08 in<\/em>
\n dermatomyositis and antisynthetase syndrome, <\/em>
\n expected to initiate in 1H26<\/em>\n <\/p>\n

\n Phase 1\/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis actively enrolling<\/em>\n <\/p>\n

\n Approximately <\/em>
\n $126.9 million<\/em>
\n cash, cash equivalents and restricted cash as of <\/em>
\n December 31, 2025<\/em>
\n , expected to support planned operations into mid-2027, including completion of ongoing Phase 3 AURORA trial<\/em>\n <\/p>\n

FREDERICK, Md., March 09, 2026 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (\u201cwe\u201d, the \u201cCompany\u201d or \u201cCartesian\u201d), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today reported financial results for the year ended December 31, 2025, and outlined recent business updates.<\/p>\n

\u201cBuilding on a productive year, we look forward to a potentially transformative 2026 as we advance Descartes-08 across several autoimmune indications,\u201d said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian. \u201cOur top priority remains delivering on our Phase 3 AURORA trial in myasthenia gravis (MG), for which we are on track to enroll approximately 100 patients. This trial represents a crucial opportunity to demonstrate the potential of Descartes-08 to improve patient outcomes and redefine the standard-of-care for MG. Descartes-08\u2019s ease of use, including, flexible, convenient outpatient administration with no preconditioning chemotherapy, combined with deep and durable responses observed through 12 months following a single course of treatment, and a favorable safety profile, underscore our belief that Descartes-08 holds significant promise to deliver meaningful benefit to patients.\u201d<\/p>\n

Dr. Brunn continued, \u201cBeyond MG, we are working to activate sites for our Phase 2 TRITON trial of Descartes-08 in myositis, which we plan to initiate in the first half of 2026. In parallel, we are also excited to explore potentially enhanced cell therapy delivery options of existing product candidates and next generation agents in development through in-vivo platforms with multiple feasibility studies underway. With an upcoming year of focused clinical execution, we believe we are well-positioned to fill the significant unmet need that remains within the autoimmune treatment landscape.\u201d<\/p>\n

\n Pipeline Progress and Anticipated Milestones<\/strong>\n <\/p>\n